Obesity therapeutics now represent ~$98B and 4.6% share, climbing to the fourth-largest category, with ~190 pipeline assets ...

Variants in GLP‑1 and GIP receptor genes partly determine weight loss and nausea risk on GLP‑1 drugs, signaling a shift from ...

Fact checked by Nick Blackmer GLP-1 medications have exploded in popularity over the last couple of years. In fact, a recent ...

Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap. Glucagon-like peptide-1 ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...

Kailera Therapeutics Inc., a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized ...

Obesity is increasingly referred to as a chronic disease. This is also how it is defined in the recommendations of scientific societies. In practice, however, many women who decide to undergo ...

Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity ...

G LP-1 medications have transformed the national conversation about obesity. Prescription medications such as semaglutide, ...

Children and adolescents should be proactively evaluated and treated for obesity, according to new guidelines from the American Academy of Pediatrics around childhood obesity. The guidelines note that ...

Hardworking Tennesseans like me have tried changes to our diets and exercise to lose weight and maintain healthy lifestyles, but sometimes, those practices are not enough. 2.6 million Tennesseans – ...